Ultrasensitive Detection of CNVs

NuProbe has developed an NGS panel using QASeq technology for the simultaneous and ultrasensitive detection of CNVs, indels, and SNVs in breast cancer. The panel has been tested on reference standards and clinical fresh frozen tissue, PMBCs, FFPE tissue, and cfDNA. Similar assays can be customized to target your biomarker needs. For information on available technology solutions, contact us.

Key Features

Sample Flexibility

Compatible with cfDNA, FFPE tissue, and other biospecimens

Simultaneous Detection

CNV detection of 18 genes and mutation profiling of 14 genes from the same sample

Low Sample Input

Results with as little as 5ng of DNA input

QASeq Assays Portfolio

Breast Cancer +HER2 CNV NGS Panel

Accurately detect SNVs and indels in 14 genes associated with breast cancer and CNVs down to 5% ploidy in HER2.

Overview

The Breast Cancer +HER2 CNV NGS Panel detects gene mutations across 84 breast cancer hotspots in 14 genes and CNVs in HER2. Using QASeq technology, the Breast Cancer +HER2 CNV NGS Panel accurately quantifies SNVs and indels down to 0.1% VAF and CNVs in HER2 at 2.05/1.95 single heterozygous copy gain/loss from cfDNA or tumor tissue.

Hotspot Mutations

AKT1, AR, BRAF, BRCA1, BRCA2, EGFR, ERBB2 (HER2), ERBB3, ERBB4, ESR1, KRAS, PIK3CA, PTEN, TP53

CNVs

ERBB2 (HER2)

Key Features

    • Detect SNVs and indels at 0.1% VAF
    • Detect CNVs at 2.05/1.95 ploidy
    • Compatible with tumor-derived or cell-free DNA

Publication Reference:

Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling. Nature Communications. (2022).

Download PDF | Go to publication

Request More Info